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OBJECTIVES We sought to assess whether pre-procedural angiographic characteristics are associated with
adverse clinical outcomes after coronary stenting with glycoprotein IIb/IIIa inhibition.
BACKGROUND Ischemic complications after balloon angioplasty are associated with pre- and post-procedural
angiographic variables. However, in the current era of stenting with IIb/IIIa inhibition, it is
unknown whether angiographic features assessed before intervention confer an increased risk
of adverse procedural and subsequent clinical outcomes.
METHODS In the Do Tirofiban and ReoPro Give Similar Efficacy Outcomes? Trial (TARGET), 4,809
patients undergoing planned stenting were randomized to tirofiban or abciximab. Baseline
demographic, clinical, and angiographic variables were obtained. Clinical end points were
recorded at 30 days and six months. The relationship between angiographic variables and
adverse clinical outcomes was assessed.
RESULTS Patients with the combination of thrombus, lesion eccentricity, and lesion length 20 mm
had a 21.4% composite incidence of death, myocardial infarction, or urgent target vessel
revascularization (TVR) at 30 days, compared with 4.2% in those patients without these
high-risk features (hazard ratio [HR] 3.24, p  0.001). After adjustment, the risk was
independently associated with thrombus (HR 1.40, p  0.034), eccentricity (HR 1.67, p 
0.001), and lesion length 20 mm (HR 1.89, p  0.001). The risk of six-month TVR was
independently associated with left anterior descending coronary artery lesions (HR 1.46, p 
0.001), restenotic lesions at baseline (HR 1.58, p  0.006), and lesion length (HR 1.19, p 
0.03).
CONCLUSIONS Patients with thrombus, eccentric lesions, or lesion length 20 mm are at high risk for
ischemic outcomes after coronary stenting, despite IIb/IIIa inhibition. Further research into
novel anti-thrombotic therapies or procedural strategies is necessary for these
patients. (J Am Coll Cardiol 2003;42:981–8) © 2003 by the American College of
Cardiology Foundation
Ischemic complications after percutaneous transluminal
coronary angioplasty (PTCA) are associated with certain
high-risk morphologic features of the treated lesion, includ-
See page 989
ing lesion length, angulation, and thrombus (1–4). How-
ever, these studies examined only post-procedure angio-
graphic variables or were performed before the advent of
glycoprotein IIb/IIIa inhibitors and routine stent usage. The
glycoprotein IIb/IIIa inhibitors (5–11) and thienopyridines
(12–17), as well as the use of intracoronary stents (18–20),
have significantly reduced the incidence of adverse clinical
events after percutaneous coronary intervention (PCI). In
this current era, little is known about the value of angio-
graphic features, assessed before intervention, in predicting
post-procedural clinical outcomes. For this reason, we
examined the recent TARGET (Do Tirofiban and ReoPro
Give Similar Efficacy Outcomes?) Trial study population of
4,809 patients undergoing planned stenting with either
intravenous tirofiban or abciximab, to determine whether
pre-procedural angiographic characteristics are associated
with an increased risk of adverse ischemic events.
METHODS
Study population. The rationale and design of the TAR-
GET trial have been previously described (21,22). In brief,
patients undergoing PCI with planned stenting were con-
sidered for enrollment. Patients with acute myocardial
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infarction (MI), cardiogenic shock, unprotected left main
coronary artery lesions, decompensated heart failure, renal
insufficiency, thrombocytopenia, or bleeding disorders were
excluded. The Human Investigational Review Board at each
site approved the study, and all patients provided written
informed consent.
Patients were randomized in a double-blind, double-
dummy design to tirofiban (10 g/kg intravenous bolus,
followed by 0.15 g/kg/min infusion for 18 to 24 h) or
abciximab (0.25 mg/kg bolus, followed by 0.125 g/kg/min
infusion, maximum 10 g/min, for 12 h). Randomization
was stratified according to the presence or absence of
diabetes mellitus. All patients received 250 to 500 mg of
aspirin within 24 h before the procedure and 75 to 325 mg
orally once daily for the duration of the study. Clopidogrel
was recommended for all patients (300 mg oral loading dose
within 2 to 6 h of the procedure, followed by 75 mg daily for
30 days). Unfractionated heparin was administered accord-
ing to a predefined nomogram at the beginning of the
procedure to a target activated clotting time of 250 s. Serum
creatine kinase (CK) and CK-MB levels were measured
every 6 h post procedure for 24 h. Clinical follow-up was
performed at 30 days and six months, and mortality was
assessed at one year.
Definitions, end points, and statistics. Baseline clinical
and demographic variables were recorded at the time of
enrollment. In addition, angiographic characteristics were
recorded at the time of the procedure, based on the
individual operator’s assessment of lesion morphology. The
primary end point of the study was the composite of death,
MI, or urgent target vessel revascularization (TVR) within
30 days. A new peri-procedural MI (within 48 h post
procedure) was defined as an elevation of the CK-MB to
three times the upper limit of normal in two separate blood
samples or by the presence of new Q waves in two or more
contiguous electrocardiographic leads. Secondary clinical
end points included each component of the primary end
point; six-month rates of death, MI, and any TVR; and
hematologic and hemorrhagic complications. The sample
size was selected to test the hypothesis that tirofiban would
not be inferior to abciximab.
Univariable analyses were performed to examine baseline
and angiographic characteristics within treatment groups.
Analyses were also performed on baseline characteristics by
angiographic findings and on angiographic findings by acute
coronary syndrome (ACS). Pearson chi-square tests were
used for categorical variables, and the Wilcoxon test was
used for continuous variables. For outcome variables, uni-
variable analyses were performed using Kaplan-Meier prod-
uct limit estimation. Survival was stratified by angiographic
factors with log-rank testing. New variables were formed for
patients with none, any one, any two, or all three of the
identified angiographic risk factors. Figures are provided
that demonstrate the estimated cumulative hazards for
30-day and six-month end points stratified by angiographic
findings.
Cox proportional hazard modeling was used to describe
30-day and six-month end points. Variables considered for
analysis included baseline, clinical, procedural, and angio-
graphic factors. The approach to modeling was to first
adjust for baseline and clinical factors. Once these adjust-
ments were made, significant angiographic factors were
determined. Stepwise selection techniques were used to
identify significant factors. Significance was determined at p
 0.05. Model validation was performed via bootstrapping.
All analyses were intention to treat.
RESULTS
Baseline angiographic characteristics. A total of 4,809
patients were randomized to tirofiban or abciximab between
December 30, 1999, and August 25, 2000. The baseline
clinical, demographic, and angiographic characteristics of
these patients are provided in Table 1. There were no
significant angiographic differences between the two treat-
ment arms of the trial. Intracoronary thrombus was noted in
9.7% of patients, and two-thirds of patients were noted to
have eccentric lesions. The majority of lesions were in native
vessels, but a small number of interventions (6.1%) were
performed on bypass grafts. Most lesions (59%) were
between 10 and 20 mm in length, and 98% of patients
demonstrated TIMI 3 flow after stenting.
Patients with intracoronary thrombus were significantly
more likely than those without thrombus to be current
smokers and to have an ACS as the indication for PCI
(Table 2). In addition, patients with intracoronary thrombus
were nearly three times as likely to have a PCI performed in
a bypass graft and had lower rates of TIMI 3 flow both
before and after the procedure. Patients with thrombus were
less likely than those without thrombus to have restenotic
lesions. Finally, patients with thrombus were more likely
than those without thrombus to have lesions longer than
20 mm (23.7% vs. 15.1%, p  0.001).
Compared with patients whose lesions were concentric,
patients with eccentric lesions were more likely to be current
smokers (22.9% vs. 19.9%, p  0.02) and were more likely
to have lesions longer than 20 mm (17.5% vs. 12.8%, p 
0.001). There were no other significant demographic or
clinical differences between these groups.
Abbreviations and Acronyms
ACS  acute coronary syndrome
CK  creatine kinase
HR  hazard ratio
LAD  left anterior descending coronary artery
MI  myocardial infarction
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary
angioplasty
TARGET  Do Tirofiban and ReoPro Give Similar
Efficacy Outcomes? trial
TVR  target vessel revascularization
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Patients with lesions 20 mm, when compared with
patients whose maximal lesion length was 20, were more
likely to be male (76.6% vs. 72.9%, p  0.03), and were less
likely to have TIMI 3 flow both before (69.8% vs. 83.3%,
p  0.001) and after the procedure (95.4% vs. 98.5%, p 
0.001). There were no other significant differences between
these two groups.
Relationship between clinical presentation and angio-
graphic findings. Patients with an ACS indication for PCI
(unstable angina pectoris, non–Q-wave MI or recent
Table 1. Baseline Characteristics Stratified By Treatment Arm
All Patients
(n  4,809)
Abciximab
(n  2,411)
Tirofiban
(n  2,398) p Value*
Demographic characteristics
Mean age in yrs ( SD) 62.3 (11.0) 62.6 (10.9) 62.1 (11.0) 0.06
Male (%) 73.5 73.5 73.5 0.96
Current smoker (%) 22.0 21.4 22.6 0.34
Diabetes mellitus (%) 23.2 23.1 23.4 0.84
Hypertension (%) 64.8 65.4 64.3 0.45
Acute coronary syndrome (%) 62.9 62.7 63.1 0.74
Angiographic characteristics
Thrombus present (%) 9.7 9.3 10.1 0.37
Eccentric lesion (%) 65.6 66.5 64.7 0.20
Restenotic lesion (%) 6.3 6.7 5.9 0.28
PCI in bypass graft (%) 6.1 6.0 6.1 0.91
Minimum TIMI flow pre-PCI (%) 0.82
0 5.1 5.3 4.9
1 3.7 3.8 3.6
2 10.1 10.3 9.9
3 81.1 80.6 81.7
Minimum TIMI flow post-PCI (%) 0.41
0 1.0 1.0 1.0
1 0.3 0.2 0.4
2 0.7 0.7 0.8
3 98.0 98.2 97.8
Maximum lesion length (%) 0.72
10 mm 24.9 25.2 24.6
10–20 mm 59.1 59.3 59.0
20 mm 15.9 15.5 16.3
*Comparison of tirofiban vs. abciximab.
PCI  percutaneous coronary intervention; TIMI  Thrombolysis In Myocardial Infarction.
Table 2. Baseline Characteristics Stratified By Presence or Absence of Intracoronary Thrombus
Thrombus
(n  463)
No
Thrombus
(n  4,314) p Value*
Mean age in yrs ( SD) 62.0 (11.2) 62.4 (10.9) 0.60
Male (%) 77.1 73.1 0.06
Current smoker (%) 31.3 21.0 0.001
Diabetes mellitus (%) 21.8 23.4 0.45
Hypertension (%) 62.4 65.1 0.25
Acute coronary syndrome (%) 77.5 61.3 0.001
Treatment with tirofiban (%) 51.8 49.6 0.37
Restenotic lesion (%) 3.7 6.6 0.01
PCI in bypass graft (%) 14.0 5.1 0.001
Minimum TIMI flow pre-PCI (%) 0.001
0 15.3 4.0
1 8.4 3.1
2 17.7 9.3
3 58.5 83.6
Minimum TIMI flow post-PCI (%) 0.001
0 2.8 0.8
1 0.6 0.3
2 2.2 0.6
3 94.4 98.4
*Comparison of patients with thrombus vs. patients with no thrombus.
Abbreviations as in Table 1.
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Q-wave MI) were two times more likely to have intracoro-
nary thrombus than those presenting with non-ACS (stable
angina or abnormal noninvasive testing) indications (12.0%
vs. 5.9%, p  0.001). Those patients with recent Q-wave
MI had the highest incidence of thrombus (28.6%). There
were no differences in the incidence of lesion eccentricity or
long lesions (20 mm) between ACS patients and non-
ACS patients (Table 3).
Univariable angiographic predictors of outcome. The
presence of thrombus, lesion eccentricity, or lesions 20
mm in length was found to be strongly associated with
adverse clinical events at 30 days and six months (Table 4,
Fig. 1). Furthermore, these three angiographic findings had
an additive association with the primary end point. In
patients with all three high-risk characteristics, the compos-
ite incidence of death/MI/urgent TVR at 30 days was
21.4%, compared with 4.2% in those without any of the
three characteristics (Log rank chi-square p value 0.001)
(Fig. 2). In keeping with the primary results of the TAR-
GET trial, patients within individual angiographic sub-
groups tended toward lower incidences of the 30-day
primary composite end point when treated with abciximab
versus tirofiban. However, among the 86 patients possessing
all three high-risk angiographic findings, the incidence of
the primary 30-day composite end point was increased
substantially in both groups to a similar level (20.5% in
patients treated with tirofiban vs. 21.3% in patients treated
with abciximab, p  0.9).
Angiographic variables were also associated with the
secondary six-month composite end point of death, MI, or
any TVR. In patients with all three high-risk characteristics,
the composite six-month end point was 29.7%, compared
with 12.9% of those patients possessing no high-risk char-
acteristics (Fig. 3).
Multivariable analysis. Cox proportional hazard modeling
was performed on all angiographic variables, in conjunction
with clinical and demographic variables previously shown to
be independent correlates of adverse outcome in this trial
(15). High-risk angiographic variables identified as inde-
pendent correlates of adverse outcome at 30 days included
intracoronary thrombus, lesion eccentricity, and lesions20
mm in length (Table 5). The presence of multiple high-risk
variables was associated with an additive risk, with a hazard
ratio (HR) of 3.24 for the 30-day primary composite end
point in the presence of all three variables. Hazard ratios
associated with these angiographic variables were similar for
the secondary combined end point of death or MI at 30
days.
Multivariable analysis of the six-month composite end
point of death, MI, or any TVR identified five independent
correlates (p  0.03): 1) country of procedure (U.S. vs.
non-U.S., HR 1.65); 2) ACS (HR 1.33); 3) PCI on left
anterior descending (LAD) coronary artery (HR 1.41); 4)
presence of thrombus (HR 1.33); and 5) maximum lesion
length 20 mm (HR 1.42). Age, lesion eccentricity, prior
clopidogrel use, and—notably—treatment arm were not
independently associated with the six-month composite end
point in this model. Multivariable analysis of the six month
end point of any TVR identified three independent angio-
graphic correlates (p  0.05): 1) PCI on LAD (HR 1.46);
2) maximum lesion length (HR 1.19); 3) and restenotic
lesion (HR 1.58).
DISCUSSION
In this analysis of a large, prospective multicenter trial of
stenting with IIb/IIIa inhibition, we have identified pre-
procedural angiographic characteristics associated with a
higher risk of adverse clinical outcomes. This effect is
independent of clinical and demographic variables known to
be associated with ischemic events in this population,
including advanced age, ACS, and thienopyridine use.
Previous studies have identified angiographic predictors
of adverse outcome, but they either examined only post-
procedural angiographic variables or were performed before
the advent of IIb/IIIa inhibition and routine use of coronary
stents (1–4). The glycoprotein IIb/IIIa inhibitors have been
shown to significantly reduce the incidence of ischemic
complications after PCI in seven large, randomized,
placebo-controlled trials (5–11). In a combined angio-
graphic analysis of the EPIC (Evaluation of 7E3 for the
Prevention of Ischemic Complications) and EPILOG
(Evaluation in PTCA to Improve Long-Term Outcome
with Abciximab GP IIb/IIIa Blockade) trials (23), 4,154
patients undergoing angioplasty or atherectomy were
treated with abciximab or placebo in addition to aspirin and
Table 3. Relationship Between Clinical Presentation and High-Risk Angiographic Findings
N Thrombus (%) Eccentric (%)
Lesion Length (%)
<10 mm 10–20 mm >20 mm
All ACS patients 3,025 12.0 66.5 23.9 59.8 16.4
Unstable angina 2,577 10.2 66.2 24.7 59.8 15.6
Non–Q-wave MI 493 20.3 69.8 20.0 61.4 18.6
Q-wave MI 263 28.6 64.7 19.9 62.1 18.0
All non-ACS patients 1,784 5.9* 64.0 26.7 58.1 15.2
Stable angina 1,046 6.2 64.5 25.8 59.8 14.4
Positive stress test 1,123 4.7 62.1 26.2 57.7 16.1
*p  0.001 for comparison of ACS vs. non-ACS patients.
ACS  acute coronary syndrome; MI  myocardial infarction.
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heparin. Abciximab was shown to reduce the 30-day com-
posite incidence of death/MI/TVR from 12.1% to 6.1%.
This risk reduction was seen across all lesion morphologies,
with the exception of lesions in degenerated saphenous vein
grafts. These studies, however, differed from the TARGET
trial, in that coronary stenting was used only for patients
with suboptimal results or for intraprocedural complica-
tions. Stenting was performed in 0.9% and 14% of the
EPIC and EPILOG patients, respectively (5,6).
In trials of coronary stenting, angiographic characteristics
have been shown to affect clinical outcomes. In a German
study of 2,894 consecutive procedures, the presence of
angiographic features (including long lesions, high-grade
stenosis, vein graft lesions, or acute thrombosis) was shown
to be associated with increased risk of procedural failure in
percutaneous stent implantation (24). In the EPISTENT
(Evaluation of Platelet IIb/IIIa Inhibition in Stenting) trial,
the presence of thrombus, major dissection, or residual
stenosis 10% after stent implantation was associated with
an increased incidence of adverse 30-day events, both with
and without concomitant IIb/IIIa inhibition (25). In the
ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa
Receptor with Integrilin Therapy) trial, patients with an-Ta
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Figure 1. Incidence of 30-day (A) and 6-month (B) primary composite
end point according to the presence of high-risk angiographic features. *p
 0.05. MI  myocardial infarction; TVR  target vessel revasculariza-
tion.
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giographic complications after stenting with IIb/IIIa inhi-
bition had a fivefold increase in a primary composite clinical
end point at 48 h (26). Similarly, in the IMPACT-II
(Integrilin to Minimize Platelet Aggregation and Coronary
Thrombosis-II) trial, patients with angiographic complica-
tions after stenting and IIb/IIIa inhibition had an increase
in the combined incidence of death/MI/urgent TVR at 24 h
(14.8% vs. 3.9%, p  0.001) (27). However, none of these
trials examined whether high-risk angiographic features
assessed before intervention confer post-procedural risk in
patients undergoing stent placement with IIb/IIIa inhibi-
tion.
Our analysis demonstrates a striking association between
thrombus, lesion length, eccentricity, and adverse ischemic
outcomes. The combination of all three features was asso-
ciated with a 21.4% event rate at 30 days, more than three
times the event rate seen in the TARGET trial as a whole.
Although the rates of adverse outcomes were driven primar-
ily by increased rates of post-procedure biomarker release,
the other components of the 30-day and six-month com-
posite end points were affected to a similar degree. Despite
the TARGET trial results demonstrating a reduction in MI
at 30 days in ACS patients treated with abciximab (vs.
tirofiban) (15), we did not note outcome differences based
on the drug used in those patients possessing high-risk
angiographic characteristics. We did, however, see a general
trend toward abciximab superiority across angiographic
subgroups, but the trial may not have had adequate power to
detect significant treatment differences in these smaller
subgroups. In this regard, it is possible that suboptimal
platelet inhibition in the tirofiban arm of the trial contrib-
uted to the adverse outcomes observed in patients with
high-risk anatomy. A recent randomized study of platelet
inhibition after administration of abciximab and tirofiban at
TARGET doses to patients with ACS suggested that the
bolus of tirofiban used in this trial may have resulted in
significantly less early platelet inhibition than that achieved
in the patients treated with abciximab (28). Whether
improved dosing regimens of tirofiban can lead to a reduc-
tion in clinical events in high-risk populations will require
Figure 2. Incidence of the 30-day primary composite end point according to the presence of angiographic variables: thrombus, lesion eccentricity, or lesion
length 20 mm. MI  myocardial infarction; TVR  target vessel revascularization.
Figure 3. Incidence of the six-month secondary composite end point according to the presence of angiographic variables: thrombus, lesion eccentricity, or
lesion length 20 mm. MI  myocardial infarction; TVR  target vessel revascularization.
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further study (29). Newer anti-thrombotic therapies, in-
cluding the low-molecular-weight heparins and direct
thrombin inhibitors, may be necessary to further reduce
complications in high-risk patients (30,31).
Angiographic follow-up was not performed in the TAR-
GET trial; therefore, in-stent restenosis cannot be directly
assessed. However, the six-month TVR rate (8.3%) may
represent a surrogate for this end point. This rate is similar
to that seen in patients treated with stenting and abciximab
in the EPISTENT trial (8.7%) (32). We identified three
angiographic characteristics that were independently asso-
ciated with increased rates of six-month TVR (LAD inter-
vention, increased lesion length, and the stenting of rest-
enotic lesions at baseline). Prior restenosis and increased
length of vessel stenting have been previously identified as
predictors of in-stent restenosis (33), and LAD intervention
is associated with restenosis after PTCA (34). Although
lesions in saphenous vein grafts have been shown previously
to be associated with increased risk of in-stent restenosis
(33), we did not observe a significant increase in six-month
TVR in patients undergoing stenting of saphenous vein
grafts.
In the TARGET trial, clopidogrel pre-treatment 2 to 6 h
before the procedure was recommended for all patients. In
the CREDO (Clopidogrel for Reduction of Events During
Observation) trial, patients pre-treated with clopidogrel (vs.
placebo) before elective stenting had a nonsignificant 18%
reduction in the 28-day composite end point of death, MI,
or urgent TVR. However, the subset of patients pre-treated
6 h before PCI had a 39% reduction in the incidence of
this end point (5.8% vs. 9.4%, p  0.05) (35). Although
most of our patients were not elective, it remains possible
that earlier pre-treatment with clopidogrel could have re-
duced adverse events.
Study limitations. Our analysis and findings may be lim-
ited by the fact that this was a retrospective analysis. In
addition, angiographic assessment was performed at the
time of PCI by individual operators and not by a core
angiographic laboratory. It is possible that the assessment of
lesion characteristics had an impact on procedural tech-
nique, or that the immediate results of the procedure
influenced the operator’s assessment of lesion characteris-
tics. Finally, the small number of events precludes sub-
analysis of the angiographic predictors within clinical
subsets.
Despite these limitations, the TARGET study provides a
unique opportunity to study the relationship between pre-
procedural angiographic findings and outcomes after coro-
nary stenting with platelet IIb/IIIa inhibition. In this large
prospective study, we have identified a population of pa-
tients that are at high risk for adverse ischemic events after
a contemporary invasive strategy incorporating stents, IIb/
IIIa inhibition, and thienopyridine use. These patients may
represent a useful study population for future trials designed
to assess the role of new anti-thrombotic therapies and
procedural strategies.
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